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Abstract
Background: The number of patients on second-line highly active antiretroviral therapy (HAART) regimens is
increasing in resource-limited settings. We describe the outcomes after 24 months for patients on LPV/r-based
second-line regimens followed up by the ESTHER programme in Phnom Penh, Cambodia.
Methods: Seventy patients who initiated second-line HAART regimens more than 24 months earlier were included,
and immuno-virological data analyzed. HIV RNA viral load was determined by real-time RT-PCR. HIV-1 drug
resistance was interpreted according to the ANRS algorithm.
Results: Of the 70 patients, two were lost to follow up, three died and 65 (92.8%) remained on second-line
treatment after 24 months of follow up (median duration of treatment: 27.4 months). At switch to second-line, the
median CD4 T cell count was 106 cells/mm3 and the median viral load was 4.7 Log10. Second-line regimens
prescribed were ddI/3TC/LPV/r (65.7%), ddI/TDF/LPV/r (10.0%), ddI/AZT/LPV/r (8.6%) and TDF/3TC/LPV/r (7.1%). The
median CD4 T cell gain was +258 cells/mm3 at 24 months (n = 63). After 24 months of follow up, 92.3% (60/65) of
the patients presented undetectable viral loads, giving an overall treatment success rate of 85.7% (CI: 75.6- 92.0) in
intent-to-treat analysis.
Conclusions: These data suggest that a LPV/r-based second-line regimen is associated with a high rate of
virological suppression and immune reconstitution after 24 months of follow up in Cambodia.
Background
Highly active antiretroviral therapy (HAART)
programmes have proven the feasibility and efficacy of
first-line HAART regimens in resource-limited settings,
similar to those reported in developed countries [1-10].
As initially emphasized stimulated by non-governmental
organizations and the World Health Organization’s
(WHO’s) “3 by 5” initiative, increasing numbers of
patients are now initiating first-line HAART regimen in
African and Asian cohorts [11-14]. At the same time,
the duration of follow up of patients on HAART is
increasing and treatment failures are becoming more
common, with an increasing number of patients having
to start second-line HAART regimens in such settings
[15,16].
Previous WHO recommendations for second-line regi-
mens proposed the choice of antiretroviral (ARV) drug
combinations, including two distinct nucleoside reverse
transcriptase inhibitors (NRTI), as didanosine (ddI), aba-
cavir (ABC), tenofovir (TDF) or lamivudine (3TC), and
one ritonavir-boosted protease inhibitor (PI/r) [17].
More recently, WHO Rapid Advice Guidelines recom-
mend the use of TDF and 3TC or emtricitabine (FTC),
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or zidovudine (AZT) and 3TC as the NRTI backbone,
together with one PI/r (LPV/r or ATV/r) [18].
However, because of the limits imposed by first-line
regimen options (limited number of available drugs,
including a thymidine analog) and because some sec-
ond-line drugs are either poorly available or prohibi-
tively expensive, the choice of second-line strategies
becomes an important and difficult issue for both the
patients and national programmes [19]. Few data on the
feasibility and efficacy of such second-line regimens in
resource-limited settings have been published so far
[20-24]. Such information would be useful for national
programmes in choosing the most appropriate and
affordable second-line combinations.
In Cambodia, the latest estimated HIV prevalence of
0.9% at the end of 2006 among adults (15-49 years)
remains one of the highest rates in south-east Asia
[25,26]; estimates are that almost 67,200 people are
infected with HIV. HAART was introduced in the coun-
try in 2001, and after a period of active scaling up, the
National Center for HIV/AIDS, Dermatology and STD
(NCHADS) recently reported that 33,287 patients were
on HAART by the end of March 2009 [27]. Treatment
failures in Cambodia are detected mostly by using
immunological criteria since HIV viral load (VL) is not
already used in routines for virological follow up.
The number of patients already on PI-based regimens
was estimated in March 2009 to be around 1145 adults,
which represents 3.9% of adult patients on HAART in
the country. The present study reports on the outcomes
of HIV adults on lopinavir/ritonavir (LPV/r)-based
second-line HAART regimens for more than 24 months,
followed up by the ESTHER programme at the Calmette
Hospital in Phnom Penh, Cambodia.
Methods
Setting
All patients evaluated in this study were part of the
ESTHER cohort, followed up at the Calmette Hospital.
The French ESTHER programme was implemented in
the Calmette Hospital in February 2003 in collaboration
with the Cambodian Ministry of Health. HAART initia-
tion began in July 2003 in accordance with WHO
recommendations and national guidelines. The initial
first-line regimen was d4T/3TC/EFV. To avoid d4T
toxicity and because of EFV supply difficulties, the
AZT/3TC/NVP combination was progressively intro-
duced and has been the initial combination since July
2004.
Patients were clinically followed every month. CD4
counts were performed every six months. VL monitor-
ing was not routinely available. Adherence support was
provided by nurses through a programme of therapeutic
patient education. After about 36 months of follow up, a
cross-sectional clinico-immunological and virological
study was performed in 2006: it revealed that 77% of the
309 included patients had shown virological success in
an intent-to-treat analysis; if only ARV-naïve patients
were considered, up to 83.5% had shown success [28].
Patients with first-line treatment failure in the
ESTHER cohort were mostly detected through cross-
sectional virological evaluations approved by the
National Ethical Committee of Cambodia; these were
performed in 2005 [29] and 2006 [28]. In addition, some
patients failing their first-line ARV regimens were also
routinely detected using clinico-immunological criteria.
Patients in first-line treatment failure were eligible for a
LPV/r-based second-line regimen.
Study population
The present study is an analysis of the efficacy of LPV/r-
based second-line regimens after 24 months of follow
up, using routinely collected follow-up data.
As of 1 March 2009, all adults who had initiated a
LPV/r-based second-line regimen more than 24 months
earlier were eligible for the analysis. Medical background
and follow-up information were routinely collected at
each consultation on standardized forms and entered
into an appropriate monitoring database.
Immunological and virological follow-up assessments
Regular immunological (every six months) and virologi-
cal assessments (once a year) were performed as part of
the monitoring of adult patients who had been receiving
HAART second-line regimens in the cohort. For the
treatment success analysis after 24 months, the first
viral load available after 24 months (VL24) of follow up
on second-line HAART regimens was taken into consid-
eration. HIV RNA viral loads (VL) was performed on
-80°C frozen plasma at the Institut Pasteur du Cam-
bodge, using the Agence Nationale de Recherche sur le
Sida (ANRS) second generation (G2) real-time RT-PCR
test [30,31]; this allows quantification of HIV-1 B and
non-B subtypes, including the A/E subtype circulating
in south-east Asia [32].
Using only 0.2 ml of plasma, the threshold of the
assay was 250 copies/ml [31]. Genotypic resistance
study was done in both the reverse transcriptase (RT)
and the protease (PR) genes using available plasma spe-
cimen presenting detectable VL. Genotypic drug resis-
tance interpretation was performed according to the
latest version of the ANRS algorithm [33]. CD4 T cell
counts were obtained using flow cytometry (Facscount,
Beckton Dickinson and Cyflow, Partec, Germania).
Statistical analysis
Patients who had not attended services for two or more
months after their last scheduled appointments (i.e.,
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three months of no visits as patients usually come to the
clinic every month) and who could not be traced were
classified as being lost to follow up and statistically con-
sidered on their last recorded visit to the clinics. CD4
gains compared with baseline at switch were calculated
every six months after second-line HAART initiation.
All analyses were performed using Stata 8.2 software
(Stata Corp., Texas, USA).
Results
Of those patients who had started a LPV/r-based
second-line regimen, 70 who had started more than
24 months earlier were included in the analysis.
Baseline characteristics and first-line HAART history
Baseline characteristics of the patients revealed that 51 of
70 (72.8%) were male and that median age was 40 years
(interquartile range [IQR]: 37-46) (Table 1). The main
initial first-line HAART regimens followed by these
patients (Table 1) were AZT/3TC/NVP (33.3%), d4T/
3TC/EFV (26.1%), d4T/3TC/NVP (17.1%) and AZT/
3TC/EFV (18.8%). The median duration on first-line
HAART regimens before switching to second-line regi-
mens was 26.6 months (IQR: 15.2-29.4). At the time of
the switch, most patients were already severely immuno-
compromised with a median CD4 count (n = 70) of 106
cells/mm3 (IQR: 42-168). The median viral load at switch
was 4.7 Log10 cp/ml (IQR: 3.1-5.4) (n = 65) (Table 1).
At switch, HIV drug resistance analysis in the reverse
transcriptase (RT) gene was available for 41 out of 70
(58.6%) patients. Since these patients were supposed to
be protease inhibitor (PI) naïve, HIV drug resistance
analysis of the protease gene was not performed. The
most common NRTI mutation at switch was the
M184V mutation (n = 41, 100%). Among non-NRTI
mutations, K103N (n = 20, 48.8%), G190A/S (n = 16,
39%) and Y181C/I (n = 9, 21.9%) mutations were most
frequently observed.
All 41 patients displayed viruses resistant to both
3TC/FTC and NVP/EFV (n = 41, 100%). When looking
at combinations of viral resistance among the 41
patients, 10 (24.4%) had viruses resistant to these four
drugs only: 3TC/FTC and NVP/EFV; one (2.4%) dis-
played viruses also resistant to D4T. Twenty-five of
them (60.9%) had viruses resistant to six drugs: 3TC/
FTC, NVP/EFV and D4T/ZDV. Three patients (7.3%)
displayed viruses resistant to seven drugs: 3TC/FTC,
NVP/EFV, D4T/ZDV and ABC; and two patients (4.8%)
showed resistance to eight drugs: 3TC/FTC, NVP/EFV,
D4T/ZDV, ABC plus DDI.
Phylogenetic analysis of the RT gene [GenBank:
HM026304 to GenBank: HM026346] revealed that 39
patients out of 41 (95.1%) were infected by CRF01_AE
viruses and two (4.9%) by HIV-1 B-subtypes.
Second-line ARV treatment
The most frequent second-line regimen used (Table 1)
was ddI/3TC/LPV/r (n = 46, 65.7%). Based on the geno-
type results and the limited number of drugs available,
some patients had to be switched to ddI/TDF/LPV/r (n =
7, 10.0%). The remaining patients were switched to TDF/
3TC/LPV/r (n = 5, 7.1%), ddI/AZT/LPV/r (n = 6, 8.6%) or
AZT/3TC/LPV/r (n = 2, 2.9%).
Immunological outcomes on second-line ARV treatment
The median CD4 cell gain on second-line regimens
(Table 2) was +80 cells/mm3 (IQR: 30-152) at six months
(n = 67), +134 cells/mm3 [IQR: 71-204] at 12 months
(n = 67) and +258 cells/mm3 [IQR: 136-425] at 24 months
(n = 63). Although these patients presented a very low
Table 1 Baseline characteristics of patients on second-
line antiretroviral regimens for more than 24 months at





Male [n (%)] 51 (72.8)
Median age [years(IQR)*] 40 (37-46)
ARV* naïve before first line [n (%)] 15 (21.4)
PI naïve at switch [n (%)] 70 (100.0)
Initial first-line ARV treatment
d4T/3TC/EFV [n (%)] 18 (26.1)
d4T/3TC/NVP [n (%)] 12 (17.1)
AZT/3TC/NVP [n (%)] 23 (33.3)
AZT/3TC/EFV [n (%)] 13 (18.8)
Other first lines [n (%)] 4 (5.8)
Follow-up time on first-line HAART* (months)
Median (IQR) 26.6 (15.2-29.4)
Characteristics at switch
CD4 T-cell counts (n) 70
Median nb cells/mm3 [n (IQR)] 106 (42-168)
Count <50 cells/mm3 [n (%)] 20 (28.6)
Median viral load (n = 65), [Log10 (IQR)] 4.7 (3.1-5.4)
Prescribed second-line ARV treatment
ddI/3TC/LPV/r [n (%)] 46 (65.7)
TDF/3TC/LPV/r [n (%)] 5 (7.1)
TDF/ddI/LPV/r [n (%)] 7 (10.0)
AZT/ddI/LPV/r [n (%)] 6 (8.6)
AZT/3TC/LPV/r[n (%)] 2 (2.9)
Other second lines [n (%)] 4 (5.7)
Follow-up time on second-line HAART
(months)
Median (IQR) 37.3 (34.2-39.0)
* IQR: interquartile range, ARV: antiretroviral, HAART: highly active
antiretroviral treatment.
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baseline CD4 count at switch, only seven of 63 (11.1%,
CI: 5.5- 2.1) patients had CD4 counts still below 200
cells/mm3 at 24 months of second-line regimens.
Virological assessment of patients on second-line
treatment
We analyzed the first VL available after 24 months of fol-
low up (VL24) for all patients included in the study. At
that time, three patients had died, two were lost to follow
up, and 65 (92.8%, CI: 84.3- 96.8) were still on second-
line treatment (for these, VL24 assessments were avail-
able). The median follow-up duration at the time of the
VL24 evaluation was 27.4 months (IQR: 25.3-29.7). VL24
was undetectable (<250 cp/ml) for 60 of 65 patients
(92.3%, CI: 83.2- 96.6) (Table 3). The VL24 of the five
patients with virological failure ranged between 2.8 and
4.4 Log10 cp/ml (Table 4). Of these, three had received
D4T/3TC/NVP, one had received D4T/3TC/EFV and
one had received AZT/3TC/EFV as first-line regimens.
At VL24 evaluation (Table 4), RT and/or PR resis-
tance profiles were available for four patients, all
infected with CRF01_AE. HIV-PR genes of patients 1
and 2 (VL = 3.6 and 2.8 Log10, respectively) could not
be amplified. RT and PR HIV drug resistance profiles of
patient 3 (VL = 4.4 Log10) did not show any resistance-
associated mutations. Patient 4 (VL = 3.9 Log10) showed
resistance to the ABC, TDF, NVP and EFV reverse
transcriptase inhibitors. This patient was also found to
have HIV resistant to indinavir (IDV) and possibly to
saquinavir (SQV) and tipranavir (TPV) [GenBank:
HM026302]. Patient 5 (VL = 3.4 Log10) displayed HIV
resistant to NVP, EFV, lopinavir (LPV), IDV, nelfinavir
(NFV) and atazanavir (ATV). He also had viruses possi-
bly resistant to TPV [GenBank: HM026303].
These five patients were boosted with second-line
adherence counselling and followed up. Two of them
died (patients 2 and 4) during this ongoing follow up
(one died because of a traffic accident and one of renal
failure). The other three were still followed on second-
line HAART regimens as of 1 March 2009.
If we consider both dead and lost-to-follow-up
patients as failure in an intention-to-treat analysis, our
data reveal that 85.7% (60/70, CI: 75.6- 92.0) of the
patients were showing second-line treatment success at
the time of VL24 evaluation.
Discussion
We report here on an analysis describing the outcomes
of 70 HIV patients on LPV/r-based second-line HAART
regimens for more than 24 months, followed at the
ESTHER programme in Phnom Penh, Cambodia. After
24 months of follow up on second-line regimens, 65
(92.8%, CI: 84.3- 96.8) remained on treatment and 60
(92.3%, CI: 83.2- 96.6) had undetectable viral loads, giv-
ing an 85.7% (CI: 75.6- 92.0) treatment success rate in
intent-to-treat analysis. A strong immune reconstitution
was observed at 24 months (+258 cells/mm3 [IQR: 136-
425]) of follow up on second-line HAART regimens.
While no specific information on adherence was avail-
able, these very good virological data revealed that these
patients were indeed adhering well despite the complex-
ity (number of pills) and the difficulties of storage con-
ditions (at 2-8°C for LPV/r) of such regimens used at
that time, demonstrating the feasibility of PI-based sec-
ond-line regimens in such resource-limited settings.
Most of these patients were switched to second-line
regimens following cross-sectional virological evaluations
performed at the ESTHER/Calmette programme. Thus, it
is important to note that this modality of switch is not
Table 2 Immunological restoration of ESTHER patients on second-line regimens at Calmette Hospital in Phnom Penh,
Cambodia
At switch n = 70 M6 n = 67 M12 n = 67 M18 n = 63 M24 n = 63 M30 n = 46
Median CD4 count (cells/mm3) 106 197 258 308 372 344
(IQR) (42-168) (113-275) (173-342) (213-427) (260-535) (249-457)
% with CD4 count:
<50 cells/mm3 28.6 1.5 3.0 3.2 0.0 0.0
<200 cells/mm3 54.3 50.7 31.3 20.6 11.1 15.2
Median CD4 count gain (cells/mm3) - + 80 + 134 + 175 + 258 + 227
(IQR) - (30-152) (71-204) (99-279) (136-425) (134-403)
Table 3 Viral load measures of patients on second-line
regimens for more than 24 months (n = 65)a
Viral load (copies/ml) N % 95% CI* Cumulative%
<250 60 92.31 85.8 - 98.8 92.31
[250-1000] 1 1.54 0 - 4.5 93.85
[1000-10,000] 3 4.62 0 - 9.7 98.46
[10,000-30,000] 1 1.54 0 - 4.5 100.0
≥30,000 0 0.0 100.0
Total 65 100.0 100.0
a taking into account the first viral load performed after 24 months of follow
up (in practice ≥21 months of follow up) under second-line treatment.
Lost-to-follow-up and dead patients (n = 5) excluded (follow up less than
24 months).
* CI: confidence interval.
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representative of what is currently done in Cambodia,
where clinico-immunological criteria are predominantly
used. On the other hand, we could reasonably assume
that such a cross-sectional survey might have detected
treatment failures earlier than if routine immunological
detection was applied.
Clearly, some patients at switch were already resistant
to some second-line NRTI drugs recommended and
available in Cambodia. Indeed, we found that all 41
patients with resistance genotype available before switch-
ing to LPV/r based second-line ARV regimens were resis-
tant to 3TC/FTC, and that 10% (four of 41) were
resistant to at least one other second-line drug, including
ddI, ABC or TDF. Thus, we can assume that the vast
majority of the 70 patients on PI-based regimens and fol-
lowed up for 24 months were resistant to 3TC.
Because of national programme recommendations, a
large majority of our patients (57%) initiated 3TC-based
triple combinations as second-line HAART regimens. It
is thus noteworthy to observe such excellent immuno-
virological outcomes after two years of follow up despite
the fact that such second-line regimens might have
worked only as dual therapy or monotherapy from their
initiation. This might be not surprising because all
patients were apparently naïve for protease inhibitors.
On the other hand, the M184V mutation, in addition
to conferring high levels of resistance to 3TC, has also
been shown to reduce viral replication capacity [34], to
increase the faithfulness of the RT [35], and to maintain
more sensitivity to 3TC than previously believed [36,37].
This led to the speculation that 3TC might still be bene-
ficial in patients harbouring the M184V mutation.
Recent data from a pilot study comparing complete
HAART interruption with the maintenance of 3TC
despite the presence of M184V mutation in salvage
therapy revealed better clinical and immunological out-
comes at 48 weeks when maintaining 3TC, with no
further accumulated mutations [38]. Whether such a
benefit of 3TC also applies to patients on second-line
regimens is still unknown and needs to be investigated.
In addition, it remains to be shown that the effective-
ness of such “non-optimal” second-line regimens after
two years could be maintained on longer periods of
follow up. In any case, the fact that such patterns of
resistance with limited options for second-line regimens
was already observed following the initial cross-sectional
survey advocates for the use of monitoring strategies
allowing early virological failure detection, as well as the
use of stronger first-line regimens with higher genetic
barriers.
Considering the five patients presenting detectable VL
after 24 months on LPV/r-based second-line regimens,
we found that two of them (patients 4 and 5) harboured
PI resistance-associated mutations. Further clinical
investigations revealed that both of these two patients
were exposed to several PIs and other RTIs before
enrolment into the ESTHER cohort. Another patient
(patient 3, Table 4), displayed no drug resistance muta-
tion at all, which could be explained by treatment inter-
ruption. The PR gene could not be amplified for the
two remaining patients (patients 1 and 2), probably
because of their low-level viral loads (2.8 and 3.6
Log10). As for first-line ARV regimens, these data sug-
gest that not being PI naïve could also be a risk factor
for treatment failure on second-line regimens.
Recently, a multicohort study analyzing patients on sec-
ond-line ARV therapy for more than six months in 27
Médecins Sans Frontières (MSF) ART programmes in
Africa and Asia reported that 18.8% of 632 patients dis-
played WHO clinical, immunological or virological criteria
of failure after a median of 11.9 months of follow up, with
cumulative probabilities showing up to 28% failures at two
years [20]. Our current study found only 7.7% (CI: 3.4-
16.8) virological failure among actively followed patients
after 24 months, which is in apparent disagreement with
the results reported by the MSF study. In fact, it is difficult
to compare these studies since each used very different
criteria to define second-line treatment failures.
Indeed, not all patients with clinical or immunological
criteria of failure had virological confirmation in the
MSF study, while all of our patients were defined virolo-
gically only. As it is known that patients with clinical or
immunological WHO criteria of failure could display
undetectable viral loads, it would be of interest to know
the rates of viological failure among those patients with
virological confirmation in the MSF study. In addition,
Table 4 Reverse transcriptase and protease resistance profiles of five patients with detectable viral load after 24
months on second-line antiretroviral regimens
Patient Age Gender Second-line ARV regimens Duration (months) VL24 Log10 RT resistance profile PR resistance profile
1 39 M 3TC DDI LPV/r 44 3.6 3TC FTC not amplified
2 37 M 3TC DDI LPV/r 28 2.8 not amplified not amplified
3 30 F 3TC DDI LPV/r 27 4.4 none none
4 42 M 3TC TDF LPV/r 34 3.9 ABC TDF NVP EFV IDV SQV/r* TPV/r*
5 48 M LPV/r fosAPV 24 3.4 NPV EFV IDV NFV ATV LPV/r TPV/r*
* Possible resistance.
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the differences observed might be cohort specific since
we analyzed a limited number of patients from one
cohort only, while the MSF study analyzed 27 distinct
cohorts and a much larger number of patients. Further
studies addressing the effectiveness of boosted protease
inhibitor-based regimens in resource-limited settings are
still needed. Detailed description of cohort characteris-
tics, including patient follow-up procedures and second-
line adherence support, will be critical for identifying
programmatic factors that might influence second-line
outcomes in such settings.
Conclusions
In conclusion, as reported by a recent Thai study [39],
we have shown promising results concerning the feasi-
bility and efficacy of PI/r-based second-line HAART
regimens after two years of follow up in a cohort in
Cambodia. However, further studies in Cambodia are
needed to confirm such long-term favourable outcomes
of second-line regimens in settings where first-line treat-
ment failure detection and switching to second-line regi-
mens do not use routine viral load and resistance
genotyping, as in the ESTHER cohort.
These data also outline the need to work further on
early treatment failure detection and on the affordability
of additional second-line drug options to optimize sec-
ond-line regimen choices. If current first-line regimens
remain the same in resource-limited settings, rando-
mized clinical trials will be critical to rapidly define the
most appropriate second-line or even third-line regi-
mens to be recommended. On the other hand, defining
stronger, affordable, alternative first-line regimens in
order to better preserve future second-line options
might also be urgently warranted.
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